Search results
-
Blog
7 Tips for Navigating the Complexities of In Vitro NAMs Studies
Discover seven tips from expert toxicologist and consultant Robin Guy on tackling key challenges for in vitro NAMs studies, from data integrity to regulatory acceptance.
-
Blog
A Professional Perspective on the FDA Roadmap Announcement on “Phasing Out” Animal Testing Requirements
Toxicologist Mary Ellen Cosenza explains the FDA’s 2025 roadmap for phasing out animal testing and its implications for drug development and safety.
-
Blog
Consultant’s Corner—Reflections from a Study Monitor and Director: A Career in Toxicology, by Bill Brock
Bill Brock reflects on his career in toxicology spanning over 40 years, sharing insights on mentorship, new technologies, and the future of toxicology and preclinical research.
-
Blog
Case Study: How We Helped a Sponsor Go From Safety Assessment to Proof-Of-Concept in 22 Months
See how Altasciences’ Acceleration Platform helped advance an incretin-based therapy to POC in ~22 months through integrated drug development.
-
Blog
Shaping the Future of Microsampling at Altasciences by Jeff Plomley
Jeff Plomley discusses how patient-centric blood microsampling can enable at-home, minimally invasive sample collection, and improve accessibility and clinical trial efficiency.